efficacy of glp 1 receptor agonists and safety LY3298176, a novel dual GIP and GLP-1 agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Clinical efficacy results from clinical

A systematic review and meta-analysis of the available RCT data showed that retatrutide-treated participants achieved a mean body weight reduction of 10.66 kg and a BMI reduction of 4.53 kg/m, with significant proportions achieving weight loss thresholds of 5%, 10%, 15%, and 20% versus placebo

Understanding how GLP-1 regulates inflammation will provide insights into the pleiotropic benefits of GLP-1 receptor (GLP-1R) agonism

DPP4i may not be as efficacious as some other classes of antidiabetic drugs, such as metformin or SGLT2 inhibitors, in lowering levels of blood glucose, especially in individuals with very high blood sugar levels [167]

(A head-to-head trial of the two medications, funded by Eli Lilly, found that patients on Zepbound lost an average of 20 percent of their weight, versus about 14 percent for those on Wegovy.) Nevertheless, its much harder to get Zepbound than Wegovy

Acta Diabetol (2020) 57(11):131526

Be clear and honest about your mission and reach trust and customer and doctor loyalty and much more